Please ensure Javascript is enabled for purposes of website accessibility

Coronavirus Vaccine Program From Pfizer and BioNTech Reports Preliminary Success

By Cory Renauer - Jul 20, 2020 at 11:38AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The race to develop a coronavirus vaccine is heating up.

BioNTech (BNTX -7.54%) and Pfizer (PFE 0.61%) released clinical trial results regarding the partners' experimental coronavirus vaccine program, BNT162, on Monday. Specifically, the partners published results from an early-stage German trial with BNT162b1, the most advanced candidate in a program designed to test four related vaccine candidates. 

This specific candidate delivers messenger RNA (mRNA) that leads to the production of the receptor-binding domain found on SARS-CoV-2, the virus that causes COVID-19. Results from the German study fell in line with positive results the partners posted earlier this month from a similar study run in the U.S. with an important new revelation.

Hand halting a gigantic coronavirus

Image source: Getty Images.

Coronavirus-ready T-cells 

So far, vaccine developers have been quick to report concentrations of antibodies produced in response to their vaccine candidates, but that doesn't really tell us whether immune systems are ready to mount an attack on SARS-CoV-2 the moment it shows up in the bloodstream.

BioNTech and Pfizer are making waves today because they observed high levels of CD4-positive and CD8-positive T-cell responses against the SARS-CoV-2 receptor-binding domain. In a nutshell, this strongly suggests injections primed these patients' immune systems to pounce on SARS-CoV-2 before it can cause any trouble.

This also suggests Moderna's (MRNA -2.09%) mRNA-based vaccine candidate, mRNA-1273, will have tough competition ahead. CD4-positive and CD8-positive T-cell responses were observed following injections of BNT162b1 that ranged in size from 1 microgram to 50 micrograms. While Moderna reported CD4-positive T-cell responses to its vaccine candidate, the company didn't mention the presence of CD8-positive T-cells, which are directly responsible for chewing up virally infected cells.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.57 (0.61%) $0.30
BioNTech SE Stock Quote
BioNTech SE
BNTX
$169.30 (-7.54%) $-13.81
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$182.94 (-2.09%) $-3.90

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.